Search
Pramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalPramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.
Categories: Drugs for Urinary Frequency and IncontinenceChromium
go.drugbank.com/drugs/DB11136ApprovedInvestigationalChromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label]. … According to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 μg and 25 μg, respectively [L1986].
Mixtures: For-2, Doctor's Choice Brand for MenLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.
Human papillomavirus type 6 L1 capsid protein antigen
go.drugbank.com/drugs/DB10299ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTIONCalcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIt is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. … [DB00146] undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity [A26353]. Calcitriol is considered to be the most potent metabolite of vitamin D in humans [A3366].
Categories: Antipsoriatics for Topical UseProducts: CITRIOPOR CAPSULAS POR 0.25 MCGBulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseZiftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
Butenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly. … [A245159] Treatment options for patients with CAD are limited.